Background
Methods
Patient population
Immunohistochemistry
Cell culture and 3-(4.5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide assay
Statistical analysis
Results
Patient characteristics
Age | median | 55 |
mean | 56.2 | |
range | 29~ 77 | |
Sex | male | 150 (97%) |
female | 5 (3%) | |
Primary tumor location | Upper | 22 (14%) |
Middle | 60 (39%) | |
Lower | 73 (47%) | |
T classification | T1 | 48 (31%) |
T2 | 31 (20%) | |
T3 | 61 (39%) | |
T4 | 15 (10%) | |
N classification | N0 | 106 (68%) |
N1 | 30 (19%) | |
N2 | 13 (9%) | |
N3 | 6 (4%) | |
7th AJCC Stage | IA | 7 (5%) |
IB | 37 (24%) | |
IIA | 25 (16%) | |
IIB | 43 (28%) | |
IIIA | 15 (9%) | |
IIIB | 6 (4%) | |
IIIC | 18 (12%) | |
IV | 4 (2%) | |
Histological grading | Grade 1 | 16 (10%) |
Grade 2 | 108 (70%) | |
Grade 3 | 31 (20%) | |
Surgical margin | Negative | 135 (87%) |
Positive | 20 (13%) | |
SIRT1 expression | Low expression | 78 (50%) |
Overexpression | 77 (50%) |
Correlation between clinicopathologic parameters and SIRT1 expression
Parameters | SIRT1 expression | |||
---|---|---|---|---|
Low | Over | P value | ||
Age | <55y/o | 32 | 37 | 0.38 |
≧55y/o | 46 | 40 | ||
Sex | Male | 75 | 75 | 1.00 |
Female | 3 | 2 | ||
Primary tumor location | U + M | 40 | 42 | 0.68 |
L | 38 | 35 | ||
T classification | T1 + T2 | 45 | 34 | 0.092 |
T3 + T4 | 33 | 43 | ||
N classification | N0 | 55 | 51 | 0.57 |
N1 + 2 + 3 | 23 | 26 | ||
7th AJCC Stage | I + II | 57 | 55 | 0.82 |
III + IV | 21 | 22 | ||
Histological grading | Grade 1 + 2 | 66 | 58 | 0.15 |
Grade 3 | 12 | 19 | ||
Surgical margin | Negative | 75 | 60 | 0.38 |
Positive | 9 | 11 |
Survival analyses
Factors | No. of patients | Overall survival (OS) | Disease-free survival (DFS) | ||
---|---|---|---|---|---|
5-yr OS rate (%) | P value | 5-yr DFS rate (%) | P value | ||
Age | |||||
< 55y/o | 69 | 54% | 0.19 | 48% | 0.10 |
≧55y/o | 86 | 37% | 29% | ||
Location | |||||
U + M | 82 | 45% | 0.84 | 35% | 0.46 |
L | 73 | 44% | 40% | ||
T classification | |||||
T1 + 2 | 79 | 64% | < 0.001a | 52% | < 0.001a |
T3 + 4 | 76 | 24% | 22% | ||
N classification | |||||
N0 | 106 | 56% | < 0.001a | 47% | < 0.001a |
N1 + 2 + 3 | 49 | 20% | 16% | ||
7th AJCC stage | |||||
I + II | 112 | 55% | < 0.001a | 46% | < 0.001a |
III + IV | 43 | 16% | 16% | ||
Histological grading | |||||
Grade 1 + 2 | 124 | 51% | 0.001a | 43% | 0.002a |
Grade 3 | 31 | 19% | 16% | ||
Surgical margin | |||||
Negative | 135 | 47% | 0.023a | 39% | 0.046a |
Positive | 20 | 25% | 25% | ||
SIRT1 expression | |||||
Low expression | 78 | 55% | 0.004a | 49% | 0.004a |
Overexpression | 77 | 34% | 26% |
Factors | Overall survival | Disease-free survival | ||
---|---|---|---|---|
HR (95% CI) | P value | HR (95% CI) | P value | |
T3 + 4 | 2.250 (1.339–3.782) | 0.002a | 2.011 (1.240–3.261) | 0.005a |
SIRT1 expression | 1.776 (1.152–2.747) | 0.009a | 1.642 (1.093–2.463) | 0.017a |
N1 + 2 + 3 | – | – | 1.967 (1.048–3.691) | 0.035a |